Abstract
Pancreatic cancer is a leading cause of cancer death worldwide and its global burden has more than doubled over the past 25 years. The highest incidence regions for pancreatic cancer include North America, Europe and Australia, and although much of this increase is due to ageing worldwide populations, there are key modifiable risk factors for pancreatic cancer such as cigarette smoking, obesity, diabetes and alcohol intake. The prevalence of these risk factors is increasing in many global regions, resulting in increasing age-adjusted incidence rates for pancreatic cancer, but the relative contribution from these risk factors varies globally due to variation in the underlying prevalence and prevention strategies. Inherited genetic factors, although not directly modifiable, are an important component of pancreatic cancer risk, and include pathogenic variants in hereditary cancer genes, genes associated with hereditary pancreatitis, as well as common variants identified in genome-wide association studies. Identification of the genetic changes that underlie pancreatic cancer not only provides insight into the aetiology of this cancer but also provides an opportunity to guide early detection strategies. The goal of this Review is to provide an up-to-date overview of the established modifiable and inherited risk factors for pancreatic cancer.
Key points
-
Smoking continues to be a leading cause of pancreatic cancer worldwide.
-
Increasing rates of diabetes and obesity will probably result in increased rates of pancreatic cancer.
-
Growing evidence indicates that high alcohol intake contributes to pancreatic cancer risk.
-
Knowledge of inherited genetic factors in pancreatic cancer continues to grow and probably explains 22–33% of pancreatic cancer risk.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies
Signal Transduction and Targeted Therapy Open Access 18 August 2023
-
Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma
BMC Cancer Open Access 17 June 2023
-
ABHD17C, a metabolic and immune-related gene signature, predicts prognosis and anti-PD1 therapy response in pancreatic cancer
Discover Oncology Open Access 05 June 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout

References
GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 4, 934–947 (2019).
He, W., Goodkind, D. & Kowal, P. An Aging World: 2015. US Census Bureau Report Number P95/16-1 (US Government Publishing Office, 2016).
Klein, A. P. Pancreatic cancer: a growing burden. Lancet Gastroenterol. Hepatol. 4, 895–896 (2019).
Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953 (2019).
International Agency for Research on Cancer. Cancer Today https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=13&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=natural-earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&show_ranking=0&rotate=%255B10%252C0%255D (2020).
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
Silverman, D. T. et al. Why do Black Americans have a higher risk of pancreatic cancer than White Americans? Epidemiology 14, 45–54 (2003).
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
Jemal, A. et al. Cancer statistics, 2006. CA Cancer J. Clin 56, 106–130 (2006).
He, J. et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB 16, 83–90 (2014).
Blackford, A. L., Canto, M. I., Klein, A. P., Hruban, R. H. & Goggins, M. Recent trends in the incidence and survival of stage 1A pancreatic cancer: a Surveillance, Epidemiology, and End Results analysis. J. Natl Cancer Inst. 112, 1162–1169 (2020).
Wood, L. D. & Hruban, R. H. Pathology and molecular genetics of pancreatic neoplasms. Cancer J. 18, 492–501 (2012).
Iodice, S., Gandini, S., Maisonneuve, P. & Lowenfels, A. B. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch. Surg. 393, 535–545 (2008).
Bosetti, C. et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann. Oncol. 23, 1880–1888 (2012).
Lynch, S. M. et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium. Am. J. Epidemiol. 170, 403–413 (2009).
Koyanagi, Y. N. et al. Smoking and pancreatic cancer incidence: a pooled analysis of 10 population-based cohort studies in Japan. Cancer Epidemiol. Biomarkers Prev. 28, 1370–1378 (2019).
Bao, Y., Giovannucci, E., Fuchs, C. S. & Michaud, D. S. Passive smoking and pancreatic cancer in women: a prospective cohort study. Cancer Epidemiol. Biomarkers Prev. 18, 2292–2296 (2009).
Zhou, J., Wellenius, G. A. & Michaud, D. S. Environmental tobacco smoke and the risk of pancreatic cancer among non-smokers: a meta-analysis. Occup. Env. Med. 69, 853–857 (2012).
Bertuccio, P. et al. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann. Oncol. 22, 1420–1426 (2011).
Araghi, M. et al. Use of moist oral snuff (snus) and pancreatic cancer: pooled analysis of nine prospective observational studies. Int. J. Cancer 141, 687–693 (2017).
Tranah, G. J., Holly, E. A., Wang, F. & Bracci, P. M. Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: a population-based study in the San Francisco Bay area. BMC Cancer 11, 138 (2011).
Marcon, A. et al. Trends in smoking initiation in Europe over 40 years: a retrospective cohort study. PLoS ONE 13, e0201881 (2018).
Yang, J. J. et al. Tobacco smoking and mortality in Asia: a pooled meta-analysis. JAMA Netw. Open 2, e191474 (2019).
Maisonneuve, P. & Lowenfels, A. B. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int. J. Epidemiol. 44, 186–198 (2015).
Rosato, V. et al. Population attributable risk for pancreatic cancer in Northern Italy. Pancreas 44, 216–220 (2015).
Everhart, J. & Wright, D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273, 1605–1609 (1995).
Huxley, R., Ansary-Moghaddam, A., Berrington de Gonzalez, A., Barzi, F. & Woodward, M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92, 2076–2083 (2005).
Bosetti, C. et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann. Oncol. 25, 2065–2072 (2014).
Elena, J. W. et al. Diabetes and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium. Cancer Causes Control. 24, 13–25 (2013).
Li, D. et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control. 22, 189–197 (2011).
Chari, S. T. et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129, 504–511 (2005).
Gupta, S. et al. New-onset diabetes and pancreatic cancer. Clin. Gastroenterol. Hepatol. 4, 1366–1372 (2006).
Munigala, S., Singh, A., Gelrud, A. & Agarwal, B. Predictors for pancreatic cancer diagnosis following new-onset diabetes mellitus. Clin. Transl. Gastroenterol. 6, e118 (2015).
Maitra, A. et al. A prospective study to establish a new-onset diabetes cohort: from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 47, 1244–1248 (2018).
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387, 1513–1530 (2016).
Stolzenberg-Solomon, R. Z. et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294, 2872–2878 (2005).
Pang, Y. et al. Diabetes, plasma glucose and incidence of pancreatic cancer: a prospective study of 0.5 million Chinese adults and a meta-analysis of 22 cohort studies. Int. J. Cancer 140, 1781–1788 (2017).
Grote, V. A. et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 54, 3037–3046 (2011).
Michaud, D. S. et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 286, 921–929 (2001).
Arslan, A. A. et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch. Intern. Med. 170, 791–802 (2010).
World Health Organization. Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2020).
Stolzenberg-Solomon, R. Z., Schairer, C., Moore, S., Hollenbeck, A. & Silverman, D. T. Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. Am. J. Clin. Nutr. 98, 1057–1065 (2013).
Nogueira, L., Stolzenberg-Solomon, R., Gamborg, M., Sorensen, T. I. A. & Baker, J. L. Childhood body mass index and risk of adult pancreatic cancer. Curr. Dev. Nutr. 1, e001362 (2017).
Yuan, C. et al. Diabetes, weight change, and pancreatic cancer risk. JAMA Oncol. 6, e202948 (2020).
Lucenteforte, E. et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann. Oncol. 23, 374–382 (2012).
Genkinger, J. M. et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol. Biomarkers Prev. 18, 765–776 (2009).
Jiao, L. et al. Alcohol use and risk of pancreatic cancer: the NIH-AARP Diet and Health Study. Am. J. Epidemiol. 169, 1043–1051 (2009).
Gapstur, S. M. et al. Association of alcohol intake with pancreatic cancer mortality in never smokers. Arch. Intern. Med. 171, 444–451 (2011).
Naudin, S. et al. Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition study. Int. J. Cancer 143, 801–812 (2018).
Yadav, D. & Lowenfels, A. B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144, 1252–1261 (2013).
Duell, E. J. et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann. Oncol. 23, 2964–2970 (2012).
Kirkegard, J., Cronin-Fenton, D., Heide-Jorgensen, U. & Mortensen, F. V. Acute pancreatitis and pancreatic cancer risk: a nationwide matched-cohort study in Denmark. Gastroenterology 154, 1729–1736 (2018).
Gandini, S., Lowenfels, A. B., Jaffee, E. M., Armstrong, T. D. & Maisonneuve, P. Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiol. Biomarkers Prev. 14, 1908–1916 (2005).
Olson, S. H. et al. Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Am. J. Epidemiol. 178, 691–700 (2013).
Cotterchio, M., Lowcock, E., Hudson, T. J., Greenwood, C. & Gallinger, S. Association between allergies and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 23, 469–480 (2014).
Gomez-Rubio, P. et al. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut 66, 314–322 (2017).
Riquelme, E. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795–806.e12 (2019).
Maisonneuve, P., Amar, S. & Lowenfels, A. B. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Ann. Oncol. 28, 985–995 (2017).
Fan, X. et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67, 120–127 (2018).
Michaud, D. S. et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 62, 1764–1770 (2013).
Schulte, A. et al. Association between Helicobacter pylori and pancreatic cancer risk: a meta-analysis. Cancer Causes Control. 26, 1027–1035 (2015).
Andreotti, G. & Silverman, D. T. Occupational risk factors and pancreatic cancer: a review of recent findings. Mol. Carcinog. 51, 98–108 (2012).
Barone, E., Corrado, A., Gemignani, F. & Landi, S. Environmental risk factors for pancreatic cancer: an update. Arch. Toxicol. 90, 2617–2642 (2016).
Gasull, M. et al. Methodological issues in a prospective study on plasma concentrations of persistent organic pollutants and pancreatic cancer risk within the EPIC cohort. Env. Res. 169, 417–433 (2019).
Antwi, S. O. et al. Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. Cancer Causes Control. 26, 1583–1591 (2015).
Camargo, J. et al. Toenail concentrations of trace elements and occupational history in pancreatic cancer. Env. Int. 127, 216–225 (2019).
Bosch de Basea, M. et al. Relationships between occupational history and serum concentrations of organochlorine compounds in exocrine pancreatic cancer. Occup. Env. Med. 68, 332–338 (2011).
Amaral, A. F. et al. Pancreatic cancer risk and levels of trace elements. Gut 61, 1583–1588 (2012).
Falk, R. T., Pickle, L. W., Fontham, E. T., Correa, P. & Fraumeni, J. F. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am. J. Epidemiol. 128, 324–336 (1988).
Friedman, G. D. & Van Den Eeden, S. K. Risk factors for pancreatic cancer: an exploratory study. Int. J. Epidemiol. 22, 30–37 (1993).
Fernandez, E., La Vecchia, C., d’Avanzo, B., Negri, E. & Franceschi, S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol.Biomarkers Prev. 3, 209–212 (1994).
Price, T. F., Payne, R. L. & Oberleitner, M. G. Familial pancreatic cancer in south Louisiana. Cancer Nurs. 19, 275–282 (1996).
Ghadirian, P. et al. Reported family aggregation of pancreatic cancer within a population-based case-control study in the francophone community in Montreal, Canada. Int. J. Pancreatol. 10, 183–196 (1991).
Coughlin, S. S., Calle, E. E., Patel, A. V. & Thun, M. J. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control. 11, 915–923 (2000).
Schenk, M. et al. Familial risk of pancreatic cancer. J. Natl Cancer Inst. 93, 640–644 (2001).
Silverman, D. T. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratog. Carcinog. Mutagen. 21, 7–25 (2001).
Jacobs, E. J. et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int. J. Cancer 127, 1421–1428 (2010).
Brune, K. A. et al. Importance of age of onset in pancreatic cancer kindreds. J. Natl Cancer Inst. 102, 119–126 (2010).
Norris, A. L. et al. Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Fam. Cancer 14, 95–103 (2015).
Petersen, G. M. et al. Pancreatic Cancer Genetic Epidemiology Consortium. Cancer Epidemiol. Biomarkers Prev. 15, 704–710 (2006).
Silverman, D. T. et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br. J. Cancer 80, 1830–1837 (1999).
Wang, L. et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 18, 2829–2834 (2009).
McWilliams, R. R. et al. Association of family history of specific cancers with a younger age of onset of pancreatic adenocarcinoma. Clin. Gastroenterol. Hepatol. 4, 1143–1147 (2006).
Singhi, A. D. et al. A histomorphologic comparison of familial and sporadic pancreatic cancers. Pancreatology 15, 387–391 (2015).
Shi, C. et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin. Cancer Res. 15, 7737–7743 (2009).
Chen, F. et al. Analysis of heritability and genetic architecture of pancreatic cancer: a PanC4 study. Cancer Epidemiol. Biomarkers Prev. 28, 1238–1245 (2019).
Lichtenstein, P. et al. Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343, 78–85 (2000).
Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).
Roberts, N. J. et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2, 41–46 (2012).
Roberts, N. J. et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 6, 166–175 (2016).
Amundadottir, L. et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet. 41, 986–990 (2009).
Petersen, G. M. et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 42, 224–228 (2010).
Wolpin, B. M. et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat. Genet. 46, 994–1000 (2014).
Childs, E. J. et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat. Genet. 47, 911–916 (2015).
Klein, A. P. et al. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat. Commun. 9, 556 (2018).
Brentnall, T. A., Bronner, M. P., Byrd, D. R., Haggitt, R. C. & Kimmey, M. B. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 131, 247–255 (1999).
Canto, M. I. et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin. Gastroenterol. Hepatol. 4, 766–781 (2006).
Canto, M. I. et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62, 339–347 (2013).
Canto, M. I. et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142, 796–804 (2012).
Vitone, L. J., Greenhalf, W., McFaul, C. D., Ghaneh, P. & Neoptolemos, J. P. The inherited genetics of pancreatic cancer and prospects for secondary screening. Best. Pract. Res. Clin. Gastroenterol. 20, 253–283 (2006).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
McCabe, N. et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: an issue of potency. Cancer Biol. Ther. 4, 934–936 (2005).
van der Heijden, M. S. et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin. Cancer Res. 11, 7508–7515 (2005).
Villarroel, M. C. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 10, 3–8 (2011).
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
Fogelman, D. et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother. Pharmacol. 76, 489–498 (2015).
Zhen, D. B. et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet. Med. 17, 569–577 (2015).
Goggins, M. et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56, 5360–5364 (1996).
Hu, C. et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 319, 2401–2409 (2018).
Yurgelun, M. B. et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet. Med. 21, 213–223 (2019).
Shindo, K. et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J. Clin. Oncol. 35, 3382–3390 (2017).
Murphy, K. M. et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 62, 3789–3793 (2002).
Hahn, S. A. et al. BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl Cancer Inst. 95, 214–221 (2003).
Couch, F. J. et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 16, 342–346 (2007).
Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 91, 1310–1316 (1999).
Mocci, E. et al. Risk of pancreatic cancer in breast cancer families from the Breast Cancer Family Registry. Cancer Epidemiol. Biomarkers Prev. 22, 803–811 (2013).
Thompson, D. & Easton, D. F. Cancer incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 94, 1358–1365 (2002).
Tischkowitz, M. D. et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137, 1183–1186 (2009).
Slater, E. P. et al. PALB2 mutations in European familial pancreatic cancer families. Clin. Genet 78, 490–494 (2010).
Grant, R. C. et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 148, 556–564 (2015).
Goldstein, A. M., Struewing, J. P., Fraser, M. C., Smith, M. W. & Tucker, M. A. Prospective risk of cancer in CDKN2A germline mutation carriers. J. Med. Genet. 41, 421–424 (2004).
Rutter, J. L. et al. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer 101, 2809–2816 (2004).
Vasen, H. F. et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int. J. Cancer 87, 809–811 (2000).
Vasen, H. et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European Expert Centers. J. Clin. Oncol. 34, 2010–2019 (2016).
Kastrinos, F. et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302, 1790–1795 (2009).
van Lier, M. G. et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am. J. Gastroenterol. 105, 1258–1264 (2009).
Giardiello, F. M. et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119, 1447–1453 (2000).
Giardiello, F. M. et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N. Engl. J. Med. 316, 1511–1514 (1987).
Lowenfels, A. B. et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Natl Cancer Inst. 89, 442–446 (1997).
Lowenfels, A. B., Maisonneuve, P., Whitcomb, D. C., Lerch, M. M. & DiMagno, E. P. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 286, 169–170 (2001).
Vitone, L. J., Greenhalf, W., Howes, N. R., Raraty, M. G. & Neoptolemos, J. P. Trypsinogen mutations in pancreatic disorders. Endocrinol. Metab. Clin. North. Am. 35, 271–287 (2006).
Whitcomb, D. C. et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat.Genet. 14, 141–145 (1996).
Whitcomb, D. C. et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 110, 1975–1980 (1996).
Schubert, S. et al. CFTR, SPINK1, PRSS1, and CTRC mutations are not associated with pancreatic cancer in German patients. Pancreas 43, 1078–1082 (2014).
Matsubayashi, H. et al. Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol. Ther. 2, 652–655 (2003).
Tamura, K. et al. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc. Natl Acad. Sci. USA 115, 4767–4772 (2018).
Zhong, J. et al. A transcriptome-wide association study identifies novel candidate susceptibility genes for pancreatic cancer. J. Natl Cancer Inst. 112, 1003–1012 (2020).
Zhang, M. et al. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget 7, 66328–66343 (2016).
Wu, C. et al. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat. Genet. 44, 62–66 (2011).
Low, S. K. et al. Genome-wide association study of pancreatic cancer in Japanese population. PLoS ONE 5, e11824 (2010).
Lin, Y. et al. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Nat. Commun. 11, 3175 (2020).
Childs, E. J. et al. Association of common susceptibility variants of pancreatic cancer in higher-risk patients: a PACGENE Study. Cancer Epidemiol. Biomarkers Prev. 25, 1185–1191 (2016).
Walsh, N. et al. Agnostic pathway/gene set analysis of genome-wide association data identifies associations for pancreatic cancer. J. Natl Cancer Inst. 111, 557–567 (2019).
US Preventive Services Task Force. Screening for pancreatic cancer: recommendation statement. Am. Fam. Physician 100, 770 (2019).
Goggins, M. et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69, 7–17 (2020).
Canto, M. I. et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 155, 740–751.e2 (2018).
Overbeek, K. A., Cahen, D. L., Canto, M. I. & Bruno, M. J. Surveillance for neoplasia in the pancreas. Best Pract. Res. Clin. Gastroenterol. 30, 971–986 (2016).
Konings, I. et al. Surveillance for pancreatic cancer in high-risk individuals. BJS Open. 3, 656–665 (2019).
Cohen, J. D. et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc. Natl Acad. Sci. USA 114, 10202–10207 (2017).
Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926–930 (2018).
Bartoli, M. et al. CT and MRI of pancreatic tumors: an update in the era of radiomics. Jpn. J. Radiol. 38, 1111–1124 (2020).
Chu, L. C. et al. Utility of CT radiomics features in differentiation of pancreatic ductal adenocarcinoma from normal pancreatic tissue. AJR Am. J. Roentgenol. 213, 349–357 (2019).
Acknowledgements
The work of the author is supported by NCI RO1CA154823, U01CA247283, NCI P50 CA62924 and P30CA006973, and the Sol Goldman Pancreatic Cancer Research Center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Peer review information
Nature Reviews Gastroenterology & Hepatology thanks the anonymous reviewers for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
National Cancer Institute. SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program: https://seer.cancer.gov/explorer/
Rights and permissions
About this article
Cite this article
Klein, A.P. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol 18, 493–502 (2021). https://doi.org/10.1038/s41575-021-00457-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-021-00457-x
This article is cited by
-
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis
BMC Gastroenterology (2023)
-
Pancreatic cancer stemness: dynamic status in malignant progression
Journal of Experimental & Clinical Cancer Research (2023)
-
Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma
BMC Cancer (2023)
-
Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications
Biomarker Research (2023)
-
Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies
Signal Transduction and Targeted Therapy (2023)